LGND - FDA approves Ligand's Zelsuvmi for treatment of molluscum
2024-01-05 17:02:45 ET
More on Ligand Pharmaceuticals
- Ligand Pharmaceuticals: A Complicated Tale
- Ligand Pharmaceuticals Inc. (LGND) Q3 2023 Earnings Call Transcript
- Ligand Pharmaceuticals Non-GAAP EPS of $1.02 beats by $0.40, revenue of $32.87M beats by $5.65M
- Ligand Pharmaceuticals Q3 2023 Earnings Preview
- Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals
For further details see:
FDA approves Ligand's Zelsuvmi for treatment of molluscum